is looking for the next breakout opportunity!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just a little common sense... those numbers couldn't possibly be right
If I'm ever getting serious about a stock, I ALWAYS check the SEC Filings for the black/white truth from the source
http://www.rasertech.com
The invisible hand is out of posts for the day, but often yahoos numbers are not accurate. Information is power but making sure the info is correct is huge. One way to do this is go through last qs or call ir to confirm, but often the free data on yahoo is often out of date or just inaccurate.
RZ looking good to me right now
Raser Technologies Announces Additional Extension Agreement with Thermo No. 1 Financing Partners
Raser Technologies, Inc. (NYSE: RZ), an energy technology company, today announced it has signed an additional extension agreement with its financing partners for the final completion of the Thermo No. 1 plant.
The contract extension amends the date by which Raser and its partners anticipate finalizing an updated agreement on the structure and final completion date of the Thermo No. 1 plant. The previous deadline was October 1, 2009, and with the new agreement, the date has been reset to October 16, 2009. The Thermo Financing Agreements provide project financing and tax equity capital for the project and the Company is amending its Thermo Financing Agreements in order to be consistent with recent tax law changes under the American Recovery and Reinvestment Act of 2009. The Company is also amending other provisions and deadlines in the Thermo Financing Agreements related to bringing the project to full capacity. We expect to reach full capacity of 10 MW by the end of the year.
“The broader amendment is expected to result in more beneficial terms for all parties involved,” said Richard Clayton, Principal Executive Officer. “It would allow us to take full advantage of the 30% grant available under the American Recovery and Reinvestment Act of 2009, as certain changes made by the Recovery Act made it advisable for us and the Thermo No. 1 financing providers to restructure the Thermo No. 1 financing arrangements. In addition, it also reflects updated plant economics. We are confident that these modifications will provide us with the flexibility we need to complete the Thermo No. 1 plant and further maximize our ability to deliver clean, renewable energy in the future.”
About Raser Technologies
Raser (NYSE: RZ) is an environmental energy technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology. Raser’s Transportation and Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about our ability to exploit available geothermal resources; our beliefs about our well field completion plan; our beliefs about the expected timing relating to the restructuring of our financial agreements; our beliefs about the economic benefits of contemplated financing structures, and our beliefs about our ability to qualify for government incentives. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; our ability to adapt our technology and third-party technology for the intended applications; our ability to secure necessary permits; our ability to attract, train and retain key personnel; and such other risks as identified in our quarterly report on Form 10-Q for the quarter ended June 30, 2009, as filed with the Securities and Exchange Commission, and all subsequent filings.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this report.
Couldn't find... can you please post?
I agree
In again... let's make some $$
RZ looking tasty
Would like to see the RSI dip below 30 though... would mean a new low
U da man Hand
lol, it's all good
definitley missed out on those two!
yep, Gold too!
Just like silver a bit more ;)
Go Silver!
Inflation seems to be taking hold...
QASP up 38%+ today! http://finance.yahoo.com/news/Quasar-Aerospace-Industries-prnews-3019459652.html?x=0&.v=8
IDOI also did well this morning, but retraced http://finance.yahoo.com/news/Quasar-Aerospace-Industries-prnews-3019459652.html?x=0&.v=8
FVE looking good, new high yesterday :Thumbsup:
__________________
I am not a registered investment advisor. All comments are my own and not to be construed as anything but personal opinion. I may be paid to comment on individual companies with my own personal opinions and am not influenced by the payor in any way to offer thoughts other than my own. >
I love Natural Gas and see $6 in 1-2 years easily, but UNG is a VERY ineffecient ETF that shouldn't be held long...
just my opinion
IDOI up 14%+ today...
Got some info from old friend
Check out QASP
Here is some DD:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=41302521
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=41481743
Also, looks like IDOI may heat up again
Alright, hope the family member gets well
yep, excited my position this morning
Nice, if it dips under 1.91, there would be some room for concern that its going to break the other way
Take a look at ACAD if you get the chance
As of June 30, 2009, the company had $70 million in total assets, $66.2 million of which was comprised of cash and investment securities available for sale. Current liabilities total $20.9 million and shareholder’s equity stands at $26.4 million. ACADIA anticipates that its cash, cash equivalents and investment securities will be greater than $40 million at December 31, 2009, and that its existing cash resources and payments from its collaborations will be sufficient to fund its operations at least into the first half of 2011.
'morning
Picked up some ACAD
Not really undervalued by the metrics I use, but seems to be a great price here and chart is poised for a move
As of June 30, 2009, the company had $70 million in total assets, $66.2 million of which was comprised of cash and investment securities available for sale. Current liabilities total $20.9 million and shareholder’s equity stands at $26.4 million. ACADIA anticipates that its cash, cash equivalents and investment securities will be greater than $40 million at December 31, 2009, and that its existing cash resources and payments from its collaborations will be sufficient to fund its operations at least into the first half of 2011.
GM Sideshow! Last day to make money
Might add some ACAD here... not really an undervalued play, but might have a nice bounce here.
It was a gem for sure, just happy to have found it
Hope they continue on the right track, they're doing well
Glad you could profit :Thumbsup:
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Sep. 1, 2009 (Business Wire) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS. Pimavanserin met the key secondary endpoint of motoric tolerability as measured using the Unified Parkinson’s Disease Rating Scale, or UPDRS. Pimavanserin was safe and well tolerated, with the frequency of adverse events generally similar in the pimavanserin and placebo arms.
The primary endpoint of the study was the mean change in SAPS scores at day 42 compared to baseline for each of the two pimavanserin treatment arms versus placebo. Patients showed marked improvements in the SAPS scores across all study arms. Mean reductions in SAPS scores were 5.9 points in the placebo arm, 5.8 points in the 10 mg pimavanserin arm, and 6.7 points in the 40 mg pimavanserin arm. Statistical significance was not achieved in either pimavanserin arm primarily due to the larger than expected improvement in placebo-treated patients.
“While we obviously are disappointed with the results of this Phase III study, we continue to believe in the potential of pimavanserin based on our clinical experience to date,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “We will thoroughly analyze these data along with the data on other secondary and exploratory endpoints over the next month to better understand the outcome of this study. Meanwhile, we are continuing with the second Phase III PDP trial with pimavanserin.”
Trial Design
The Phase III trial was a multi-center, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of pimavanserin in patients with PDP. A total of 298 patients were enrolled in the trial and randomized to one of three study arms, including two different doses of pimavanserin (10 mg or 40 mg) and placebo. Patients received oral doses of either pimavanserin or placebo once daily for six weeks. Patients remained on stable doses of their existing anti-Parkinson’s therapy throughout the study. The primary endpoint was antipsychotic efficacy as measured using the hallucinations and delusions domains of the SAPS. The key secondary endpoint was motoric tolerability as measured using Parts II and III of the UPDRS.
About Pimavanserin
Pimavanserin is a 5-HT2A receptor inverse agonist in Phase III development as a treatment for Parkinson’s disease psychosis. This new chemical entity, which was discovered by ACADIA, is a small molecule that can be taken orally as a tablet once-a-day. ACADIA and Biovail have formed a collaboration to co-develop and commercialize pimavanserin for neurological and psychiatric indications, including Parkinson’s disease psychosis (PDP) and Alzheimer’s disease psychosis (ADP), in the United States and Canada. ACADIA retains rights to pimavanserin in the rest of the world.
About Parkinson’s Disease Psychosis
According to the National Parkinson Foundation, over 1.5 million people in the United States suffer from Parkinson’s disease. Up to 40 percent of patients with Parkinson’s disease may develop psychotic symptoms, commonly consisting of visual hallucinations and delusions. Currently there is no therapy in the United States approved to treat PDP. The development of psychosis in patients with Parkinson’s disease is associated with increased caregiver burden, nursing home placement, and increased mortality.
Anyone been watching my CSGH?
Called at .25 in March
Anyone have thoughts on ACAD?
Looks poised to me...
Nice bro!
haha nice
Hard to say
Great trade!
Nice! :)
Natural gas had a nice bounce
I wouldn't hold onto UNG though. Might be early, but I've sold. Not the best ETF out there, but unfortunetely not much better for Natural Gas
No clue, but I wouldn't expect this bounce to last long if it doesn't reverse soon... just my thoughts
Here you go
After the chart updates for the close, maybe the money flows will change
A beautiful bounce for sure!
Money Flows still need to turn though
Calling the whole fleet
.142
RSI is looking great
STOCH is looking great
Wm%r is looking great
Other than MFI though, all money flows are still pointing down
Overall, it's looking up, but it might be a temporary bump rather than a reversal if money flows don't confirm the move
GM
Yash up 19%